Investment Analysts’ Weekly Ratings Changes for Cardinal Health (CAH)

Cardinal Health (NYSE: CAH) has recently received a number of price target changes and ratings updates:

• 8/19/2026 – Cardinal Health was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 8/19/2026 – Cardinal Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $276.00 price target on the stock.
• 8/19/2026 – Cardinal Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $276.00 price target on the stock.
• 8/13/2026 – Cardinal Health had its price target raised by TD Cowen from $275.00 to $280.00. They now have a “buy” rating on the stock.
• 8/13/2026 – Cardinal Health had its price target raised by Barclays PLC from $258.00 to $275.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Cardinal Health had its price target raised by JPMorgan Chase & Co. from $215.00 to $260.00. They now have a “neutral” rating on the stock.
• 8/12/2026 – Cardinal Health had its price target raised by Morgan Stanley from $255.00 to $265.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Cardinal Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $270.00 price target on the stock.
• 8/12/2026 – Cardinal Health had its price target raised by UBS Group AG from $274.00 to $280.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Cardinal Health had its price target raised by Mizuho from $240.00 to $250.00. They now have an “outperform” rating on the stock.
• 8/12/2026 – Cardinal Health had its price target raised by Citigroup Inc. from $265.00 to $280.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Cardinal Health had its price target raised by Wells Fargo & Company from $245.00 to $277.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Cardinal Health had its price target raised by Robert W. Baird from $251.00 to $274.00. They now have an “outperform” rating on the stock.
• 8/11/2026 – Cardinal Health was given a new $292.00 price target by Leerink Partners.
• 8/5/2026 – Cardinal Health was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 7/24/2026 – Cardinal Health had its price target raised by Citigroup Inc. from $245.00 to $265.00. They now have a “buy” rating on the stock.
• 7/23/2026 – Cardinal Health had its price target raised by Mizuho from $235.00 to $240.00. They now have an “outperform” rating on the stock.
• 7/20/2026 – Cardinal Health had its price target raised by UBS Group AG from $260.00 to $274.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Cardinal Health had its price target raised by TD Cowen from $255.00 to $275.00. They now have a “buy” rating on the stock.
• 7/4/2026 – Cardinal Health was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Cardinal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be given a $0.5158 dividend. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $2.06 annualized dividend and a yield of 0.9%. Cardinal Health’s dividend payout ratio (DPR) is presently 28.49%.

Insider Buying and Selling

In other news, CEO Stephen M. Mason sold 35,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $236.40, for a total transaction of $8,274,000.00. Following the sale, the chief executive officer directly owned 18,061 shares in the company, valued at $4,269,620.40. This trade represents a 65.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jason M. Hollar sold 80,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the completion of the transaction, the chief executive officer directly owned 235,132 shares of the company’s stock, valued at approximately $55,430,017.68. The trade was a 25.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 210,271 shares of company stock valued at $49,626,657. 0.12% of the stock is currently owned by company insiders.

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.